Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts

This week, 27 April 2025:

  1. Treatment-resistant hypertension
  2. Influenza transmission
  3. Nanoplastics in human brains
  4. Malaria elimination
  5. Chikungunya vaccine

  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 62 articles:
HTML format



Single Articles


    January 2025
  1. LEE B, Chang SJ, Kwon BS, Son JH, et al
    Correction: Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
    PLoS One. 2025;20:e0317158.
    PubMed     Abstract available


  2. TJOKROPRAWIRO BA, Novitasari K, Ulhaq RA, Sulistya HA, et al
    Investigation of the trends and associated factors of ovarian cancer in Indonesia: A systematic analysis of the Global Burden of Disease study 1990-2021.
    PLoS One. 2025;20:e0313418.
    PubMed     Abstract available


  3. TAL O, Zahavi T, Sinberger LA, Salmon-Divon M, et al
    Unlocking prognostic potential: A genomic signature of caloric restriction in patients with epithelial ovarian cancer.
    PLoS One. 2025;20:e0317502.
    PubMed     Abstract available


  4. ZHANG J, Gangwar S, Bano N, Ahmad S, et al
    Probing the role of Coniferin and Tetrahydrocurcumin from Traditional Chinese medicine against PSAT1 in early-stage ovarian cancer: An in silico study.
    PLoS One. 2025;20:e0313585.
    PubMed     Abstract available


  5. LI S, Wang Z, Huang HD
    Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations.
    PLoS One. 2025;20:e0317115.
    PubMed     Abstract available


  6. ALIZADEH H, Kerachian S, Babashah S, Soltani BM, et al
    Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian endometrioid carcinoma cell line.
    PLoS One. 2025;20:e0318740.
    PubMed     Abstract available


  7. DE AMORIM IFG, Melo CPS, Pereira RA, Cunha SM, et al
    Association of a CHEK2 somatic variant with tumor microenvironment calprotectin expression predicts platinum resistance in a small cohort of ovarian carcinoma.
    PLoS One. 2025;20:e0315487.
    PubMed     Abstract available


  8. BAO Q, Wang Z, Yang T, Su X, et al
    Curcumin induces mitochondrial dysfunction-associated oxidative DNA damage in ovarian cancer cells.
    PLoS One. 2025;20:e0319846.
    PubMed     Abstract available


    January 2024
  9. YOO MY, Woo KJ, Kang SY, Moon BS, et al
    Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema.
    PLoS One. 2024;19:e0296466.
    PubMed     Abstract available


  10. WANG G, Fu J, Liu M, Zheng Q, et al
    CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
    PLoS One. 2024;19:e0277872.
    PubMed     Abstract available



  11. Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
    PLoS One. 2024;19:e0298444.
    PubMed    


  12. YONG CM, Yehgambaram PAP, Lee SWH
    Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    PLoS One. 2024;19:e0298130.
    PubMed     Abstract available


  13. DING H, Hu B, Guo R
    Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer.
    PLoS One. 2024;19:e0298125.
    PubMed     Abstract available


  14. MIKHAEL S, Kurdi A, Khoueiry-Zgheib N, Tahtouh R, et al
    Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
    PLoS One. 2024;19:e0298127.
    PubMed     Abstract available


  15. KANG J, Na K, Kang H, Cho U, et al
    Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    PLoS One. 2024;19:e0298128.
    PubMed     Abstract available


  16. LI L, He L, Guo W, Ma J, et al
    PMFFNet: A hybrid network based on feature pyramid for ovarian tumor segmentation.
    PLoS One. 2024;19:e0299360.
    PubMed     Abstract available


  17. CHEN Z, Wang C, Ding J, Yu T, et al
    Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
    PLoS One. 2024;19:e0291149.
    PubMed     Abstract available


  18. MEHRA T, Lupatsch JE, Kossler T, Dedes K, et al
    Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
    PLoS One. 2024;19:e0301271.
    PubMed     Abstract available


  19. LI N, Jin S, Wu J, Ji H, et al
    Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    PLoS One. 2024;19:e0299504.
    PubMed     Abstract available


  20. REID F, Adams T, Adel RS, Andrade CE, et al
    The every woman study low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer.
    PLoS One. 2024;19:e0298154.
    PubMed     Abstract available


  21. PARK K, Kwon JY, Song JM, Pyeon SY, et al
    Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer.
    PLoS One. 2024;19:e0299205.
    PubMed     Abstract available


  22. HOSOKAWA S, Norimatsu Y, Shinagawa A, Kurokawa T, et al
    Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.
    PLoS One. 2024;19:e0304420.
    PubMed     Abstract available


  23. KIM NK, Suh DH, Kim K, No JH, et al
    High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
    PLoS One. 2024;19:e0304704.
    PubMed     Abstract available


  24. KARSTENSEN S, Kaiser K, Moos C, Poulsen TS, et al
    DNA alterations in ovarian adult granulosa cell tumours: A scoping review protocol.
    PLoS One. 2024;19:e0303989.
    PubMed     Abstract available


  25. NUNEZ-RIOS JD, Reyna-Jeldes M, Mata-Martinez E, Campos-Contreras ADR, et al
    Extracellular ATP/P2X7 receptor, a regulatory axis of migration in ovarian carcinoma-derived cells.
    PLoS One. 2024;19:e0304062.
    PubMed     Abstract available


  26. JANG DH, Lee HG, Lee B, Kang S, et al
    Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study.
    PLoS One. 2024;19:e0305360.
    PubMed     Abstract available


  27. ZHAO S, Wang L, Ouyang M, Xing S, et al
    Polyploid giant cancer cells induced by Docetaxel exhibit a senescence phenotype with the expression of stem cell markers in ovarian cancer cells.
    PLoS One. 2024;19:e0306969.
    PubMed     Abstract available


  28. ANCHOORI RK, Tseng SH, Tsai HL, Palande V, et al
    Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.
    PLoS One. 2024;19:e0305710.
    PubMed     Abstract available


  29. MA MC, Lavi ES, Altwerger G, Lin ZP, et al
    Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
    PLoS One. 2024;19:e0305273.
    PubMed     Abstract available


  30. CARTER R, Petrik JJ, Moorehead RA
    Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells.
    PLoS One. 2024;19:e0307178.
    PubMed     Abstract available


  31. PATRA A, Ali SS, Devi NM, Qadeer AS, et al
    Prevalence of BRCA mutation in breast and ovarian cancer among women in India: A systematic review and meta-analysis protocol.
    PLoS One. 2024;19:e0306612.
    PubMed     Abstract available


  32. TANG F, Hummitzsch K, Rodgers RJ
    Unique features of KGN granulosa-like tumour cells in the regulation of steroidogenic and antioxidant genes.
    PLoS One. 2024;19:e0308168.
    PubMed     Abstract available


  33. HOLMLUND S, Collins E, Lalos A, Idahl A, et al
    From symptoms to surgery-A pathway through uncertainty and hope: An interview study of women facing ovarian surgery.
    PLoS One. 2024;19:e0307666.
    PubMed     Abstract available


  34. ISINGIZWE ZR, Mortan LF, Benbrook DM
    Platelet and epithelial cell interations can be modeled in cell culture, and are not affected by dihomo-gamma-linolenic acid.
    PLoS One. 2024;19:e0309125.
    PubMed     Abstract available


  35. KAUTZ-FREIMUTH S, Lautz Z, Shukri A, Redaelli M, et al
    Decisional conflict and knowledge in women with BRCA1/2 pathogenic variants: An exploratory age group analysis of a randomised controlled decision aid trial.
    PLoS One. 2024;19:e0311432.
    PubMed     Abstract available


  36. YOSHIDA-COURT K, Karpinets TV, Mitra A, Solley TN, et al
    Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
    PLoS One. 2024;19:e0314643.
    PubMed     Abstract available


  37. MOGI K, Yoshihara M, Emoto R, Miyamoto E, et al
    Histology-specific long-term oncologic outcomes in patients with epithelial ovarian cancer who underwent complete tumor resection: The implication of occult seeds after initial surgery.
    PLoS One. 2024;19:e0311421.
    PubMed     Abstract available


  38. KIM K, Khazan N, McDowell JL, Snyder CWA, et al
    The NF-kappaB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
    PLoS One. 2024;19:e0314564.
    PubMed     Abstract available


  39. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    PubMed     Abstract available


  40. RUSSO D, Spina A, Portella L, Bello AM, et al
    The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.
    PLoS One. 2024;19:e0314735.
    PubMed     Abstract available


  41. PERAMPALAM P, McDonald JI, Dick FA
    GO-CRISPR: A highly controlled workflow to discover gene essentiality in loss-of-function screens.
    PLoS One. 2024;19:e0315923.
    PubMed     Abstract available


  42. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    Correction: A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2024;19:e0316114.
    PubMed     Abstract available


  43. WANG H, Han X, Niu S, Cheng H, et al
    DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion channels and stacked graph convolution.
    PLoS One. 2024;19:e0315924.
    PubMed     Abstract available


  44. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Novotny GW, Hogdall CK, et al
    Correction: Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2024;19:e0315859.
    PubMed     Abstract available


    January 2023
  45. HAWARDEN A, Price M, Russell B, Wilson G, et al
    A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
    PLoS One. 2023;18:e0281798.
    PubMed     Abstract available


  46. JLASSI A, Manai M, Morjen M, Sahraoui G, et al
    VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    PLoS One. 2023;18:e0278849.
    PubMed     Abstract available


  47. EBRING C, Marlin R, Macni J, Vallard A, et al
    Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
    PLoS One. 2023;18:e0278757.
    PubMed     Abstract available


  48. NUNES PEREIRA P, Francoise Derchain S, Yoshida A, Hoelz de Oliveira Barros R, et al
    Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.
    PLoS One. 2023;18:e0283212.
    PubMed     Abstract available


  49. GOLDSBURY DE, Vassallo A, Weber MF, Steinberg J, et al
    Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study.
    PLoS One. 2023;18:e0282851.
    PubMed     Abstract available


  50. KIM NK, Suh DH, Kim K, Kim YB, et al
    Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    PLoS One. 2023;18:e0284753.
    PubMed     Abstract available


  51. LOPACINSKA-JORGENSEN J, Petersen PHD, Oliveira DVNP, Hogdall CK, et al
    Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
    PLoS One. 2023;18:e0282576.
    PubMed     Abstract available



  52. Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2023;18:e0285545.
    PubMed    


  53. WU X, Lu W, Jiang C, Zhang D, et al
    Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    PLoS One. 2023;18:e0284825.
    PubMed     Abstract available


  54. ANCHOORI RK, Anchoori V, Lam B, Tseng SH, et al
    Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
    PLoS One. 2023;18:e0285221.
    PubMed     Abstract available


  55. LIU H, Ma S, Chen X, Wu H, et al
    Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis.
    PLoS One. 2023;18:e0286650.
    PubMed     Abstract available


  56. CHEN B, Lu X, Zhou Q, Chen Q, et al
    PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    PLoS One. 2023;18:e0290031.
    PubMed     Abstract available


  57. MOATAMED NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, et al
    Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
    PLoS One. 2023;18:e0291361.
    PubMed     Abstract available


  58. MUHAMMAD S, Azwan RJ, Rita RS, Susanti R, et al
    The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients.
    PLoS One. 2023;18:e0292282.
    PubMed     Abstract available


  59. LEE B, Chang SJ, Kwon BS, Son JH, et al
    Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
    PLoS One. 2023;18:e0294647.
    PubMed     Abstract available


  60. ROBERTSON SE, Yasukawa M, Marchion DC, Xiong Y, et al
    Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.
    PLoS One. 2023;18:e0294448.
    PubMed     Abstract available



  61. Retraction: SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells via Src Kinase.
    PLoS One. 2023;18:e0295163.
    PubMed    


  62. TAO F, Ruan S, Liu W, Wang L, et al
    Correction: Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2023;18:e0296410.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.